Boston, USA 4 September 2023 - Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report –“Gallbladder Cancer: Global Clinical Trials Landscape Report”.
According to the report, biopharma companies have initiated approximately 250 ongoing clinical trials in gallbladder cancer (GBC) since 2016, with the Asia-Pacific region playing a pivotal role in over 50% of these trials, while more than 40% were conducted in the United States and Europe.
GBC represents the most prevalent type of biliary tract cancer globally, accounting for 80%-95% of cases, with more than 1 million new cases and more than 80,000 deaths recorded in 2020.
The global age-standardized incidence and mortality for GBC is 1.20 and 0.84 per 100,000 people respectively. Asia leads the world in both incidence and mortality cases, with 82,000 and 62,300 cases, respectively, representing 70% of global occurrences.
“Due to its large population and moderate volume of studies, the Asia-Pacific region has a low competing trial risk with a trial density about 17 times less than that of the US and about 4 times lower than Europe,” states the Report.
According to the Report GBC is the sixth most common kind of gastrointestinal cancer and is more prevalent in women than in men. The leading causes are high estrogen levels, which are more common in women, and an abnormal pancreatic obstruction which is more common in people from Asia.
Additionally, the report delves into disease cases and mortality trends by region, including:
- By 2030, GBC cases and mortality in Asia is predicted to reach 142,193 and 109,122 respectively.
- Europe had incidence and mortality cases of about, 12,570 and 8,717 cases, respectively in 2020.
- The US reported over 4,600 incident cases and about 2,300 deaths in GBC in 2020. According to the American Cancer Society estimates, there will be around 12,220 new cases and approximately 4,510 deaths due to GBC in 2023 in the country.
- Canada reported an incidence of over 500 cases with an ASIR of about 0.66 per 100,000 population in 2020.
Novotech has more than 3,000 employees operating across 25 geographies, with 34 office locations, including Greater China, South Korea, Australia, New Zealand, the US, and Europe.
The CRO offers biotechs a unique and unparalleled suite of early to late-phase services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023 and the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2022 award. Additionally, the company was honored with the Asia-Pacific Contract Research Organization Company of the Year Award. Its commitment to collaboration is evident in the 50 Leading Site Partnership agreements it has signed over the past three years.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.
Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit: https://novotech-cro.com/talk-to-an-expert